FDA Awards Clearance for LungVision Navigation System to Revolutionize the Treatment of Lung Lesions

Pharma

May 17, 2017

Medical device company Body Vision Medical reported on Monday the receipt of clearance from the U.S. Food and Drug Administration (FDA) to market its first LungVision platform to the medical community to revolutionize, diagnose and treat peripheral lung lesions.

LungVision, which is a novel imaging system that enables accurate real-time navigation and lesion localization during bronchoscopic procedures, demonstrated outstanding results through the company’s multicenter clinical trials in the U.S.

Utilizing a sophisticated augmented reality approach, LungVision allows physicians to plan, visualize and track endobronchial tools and radiolucent lesions in real time. LungVision’s synergistic imaging merges intraoperative fluoroscopy with preoperative high-resolution imaging, including computed tomography, added the company.

Original headline: Body Vision Medical Awarded U.S. FDA Clearance for LungVision Navigation System to Revolutionize the Treatment of Lung Lesions

Copyright 2017 Normans Media Limited. All Rights Reserved.

Copyright © LexisNexis, a division of Reed Elsevier Inc. All rights reserved.  
Terms and Conditions    Privacy Policy

Quality News Today is an ASQ member benefit offering quality related news
from around the world every business day.

ASQ is a global community of people passionate about quality, who use the tools, their ideas and expertise to make our world work better. ASQ: The Global Voice of Quality.